by Brandon Tudor | Aug 8, 2026 | Blog
Published August 7, 2026 in Nature Reviews Gastroenterology & Hepatology, “The dynamic spectrum of steatotic liver disease: the global perspective” makes an important point for patients: fatty liver disease is not always caused by just one thing. Metabolic...
by Brandon Tudor | Aug 5, 2026 | Blog
Here’s a concise summary of the RADx® Tech Independent Test Assessment Program (ITAP) for Hepatitis C Virus (HCV) RNA Near-Patient Diagnostics (2026): Executive Summary The NIH/NIBIB RADx® Tech Independent Test Assessment Program (ITAP) is seeking to accelerate...
by David Sires | Aug 3, 2026 | Blog
Here’s a plain-English summary of the article titled “Liver Imaging Reporting and Data System (LI-RADS): A Comprehensive Review,” from Cureus, dated 07/31/2026, for patients and families: Understanding LI-RADS: A Guide for Patients Source: Liver...
by David Sires | Jul 30, 2026 | Blog
The paper titled “Comparison of Factors Associated With 30-Day and 90-Day Readmission Among a Global Cohort of Patients Hospitalised With Cirrhosis” is a large international prospective study examining what predicts 30-day versus 90-day hospital...
by Pete Celano | Jul 28, 2026 | Blog
Details here: https://www.who.int/campaigns/world-hepatitis-day/2026
by Brandon Tudor | Jul 26, 2026 | Blog
The 05/27/2026 article “GLP-1s Gain Traction for Treating Fatty Liver Disease” central message is that GLP-1 receptor agonists (particularly semaglutide/Wegovy and tirzepatide) are rapidly moving from “weight-loss drugs” to becoming mainstream...
